Low survival probability was found in patients with high expression of NAT10 (Fig. 3c), age ≥ 65 (Fig. 3d), stage III and IV disease (Fig. 3e), HPV-negative status (Fig. 3f) and recurrent tumours (Fig. 3g). Here, NAT10 is linked to neoplasm.